The COVID-19 pandemic proved that faster regulatory processes can get new medicines to patients sooner, and this centre aims to make that speed a permanent feature of drug development. The problem is that digital tools like AI, machine learning, and complex computer models are advancing far faster than the regulatory frameworks needed to approve them. Without clear rules, regulators cannot trust these tools, companies cannot use them efficiently, and patients miss out on faster access to safer, cheaper medicines. This UK Centre for Excellence will bring together industry, academia, and regulators to build the 21st-century regulatory science needed for digital transformation in medicines chemistry, manufacturing, and control. If successful, it will create harmonised guidance across digital tools, address the "black-box" nature of some AI models, resolve data security concerns, and build public trust. The result could be a pharmaceutical manufacturing system that is more efficient, more environmentally sustainable, and better able to deliver affordable medicines—without compromising patient safety.
View original technical description
The COVID-19 pandemic demonstrated vividly that regulatory innovation can accelerate the speed of access to new medicines for patients. Continuing to ensure reliable access to affordable, safe, effective and environmentally sustainable medicines requires rapid medical, scientific, engineering and digital innovation across industry, academia, government and regulators. This innovation is underpinned and enabled by digital technologies such as Al/ML, blockchain, increased simulation power and increasingly complex mechanistic and hybrid models. These technologies develop at an ever-increasing rate, and it is essential that regulatory processes can keep pace to benefit from the greater efficiency and speed digital transformation brings whilst assuring patient safety remains paramount. This UK Centre for Excellence in Regulatory Science and Innovation for digital tools in medicine's chemistry, manufacturing and control will deliver the 21st-century regulatory science and innovation needed to unlock the benefits of the digital transformation of medicines development and manufacturing for the pharmaceutical industry, regulators, and society. Collaboration through this network will build clear regulatory frameworks to address sector-specific challenges, including harmonisation of guidance across different digital tools, the complexity and black-box nature of some models, data quality and security concerns, regulatory expertise shortages, and trust issues among patients and the public
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know